Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    Change Detected
    Summary
    A new resource titled 'Helpful Links Provided by Andrea Ardizzoni' has been added, featuring information on Cabozantinib (XL184), highlighting its role as a novel MET and VEGFR2 inhibitor that suppresses metastasis, angiogenesis, and tumor growth.
    Difference
    0.6%
    Check dated 2024-07-25T17:17:37.000Z thumbnail image
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has expanded to include 11 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.2%
    Check dated 2024-07-23T14:45:14.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.0%
    Check dated 2024-07-16T08:34:02.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The website has removed information about Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, and helpful links provided by Andrea Ardizzoni from the University of Bologna.
    Difference
    0.6%
    Check dated 2024-07-05T17:24:03.000Z thumbnail image
  8. Check
    24 days ago
    Change Detected
    Summary
    The value in the web page has been updated to include an additional DOI (doi: 10.1200/JCO.2016.67.2352) for the publication by Masters GA et al. This change likely reflects an erratum or additional information added to the original publication.
    Difference
    0.0%
    Check dated 2024-07-03T14:43:34.000Z thumbnail image
  9. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.0%
    Check dated 2024-07-02T14:22:54.000Z thumbnail image

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.